ProCE Banner Activity

OPTIMISMM: Phase III Trial of Pomalidomide, Bortezomib, Low-Dose Dexamethasone vs Bortezomib, Low-Dose Dexamethasone Alone in Lenalidomide-Exposed RRMM

Slideset Download
Conference Coverage
The addition of pomalidomide to bortezomib and low-dose dexamethasone extends PFS vs bortezomib and low-dose dexamethasone alone in patients with relapsed/refractory multiple myeloma who have previously received lenalidomide.

Released: June 03, 2018

Expiration: June 02, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen